Repare Therapeutics To Regain Global Development, Commercialization Rights To Camonsertib (RP-3500), As Roche Notified That, Effective May 7, 2024, It Is Terminating License And Collaboration Agreement
Author: Benzinga Newsdesk | February 12, 2024 05:10pm
Roche notified Repare that, effective May 7, 2024, it is terminating its worldwide license and collaboration agreement for the development and commercialization of camonsertib following a review of Roche's pipeline and evolving external factors. Repare has met all obligations under the Roche agreement to date, and recently earned a $40 million milestone payment from Roche. Repare continues to expect that its existing cash, cash equivalents, and marketable securities will provide sufficient capital to fund planned operations into mid-2026.
Posted In: RHHBF RHHBY RPTX